Preserving Phosphatidylcholine Integrity in a High-Stability Soy Lecithin Softgel System: Implications for Hepatic Lipid Homeostasis

Yassine  Igoundaz; Haruto Sato; Marcus  Lane

doi:10.51699/xmf2fp56

Authors

Yassine Igoundaz National Laboratory of Medicine LLC, USA
Haruto Sato National Laboratory of Medicine LLC, USA
Marcus Lane National Laboratory of Medicine LLC, USA

DOI:

https://doi.org/10.51699/xmf2fp56

Keywords:

soy lecithin, phosphatidylcholine, choline, hepatic lipid homeostasis, MASLD, oxidative stability, softgel

Abstract

Phosphatidylcholine (PC) is a major hepatocyte phospholipid and a choline-bearing substrate for membrane renewal and lipoprotein assembly. We evaluated a stabilized soybean-lecithin softgel and placed its physicochemical performance beside human evidence on choline and phosphatidylcholine in hepatic physiology. The NVTIA® fill contains 75.00% fluid soybean lecithin, 24.52% caprylic/capric triglyceride, 0.34% mixed tocopherols, and 0.14% L-ascorbyl palmitate. Processing used low-temperature vacuum dehydration, nitrogen-protected mixing, vacuum degassing, and filtration. After 30 days at 40°C/75% relative humidity, the optimized system retained 96.4% PC, with a peroxide value of 3.5 mmol/kg and 0.8% oil leakage. Comparator formulations that removed antioxidant protection, changed the carrier oil, or increased moisture/oxygen exposure showed lower PC retention and/or higher peroxide values. Human feeding studies show that choline availability is necessary for hepatic integrity, and contemporary MASLD trials of essential phospholipids or phosphatidylcholine report changes in steatosis, liver biochemistry, oxidative-stress measures, or related metabolic endpoints. The experimental result is therefore a delivery result: the formulation maintains a defined choline-bearing phospholipid matrix over storage. That platform can be taken forward into pharmacokinetic and liver-focused human studies with verified PC exposure.

References

[1] S. H. Zeisel, “Choline: Critical role during fetal development and dietary requirements in adults,” Annu. Rev. Nutr., vol. 26, pp. 229-250, 2006, doi: 10.1146/annurev.nutr.26.061505.111156.

[2] S. H. Zeisel et al., “Choline, an essential nutrient for humans,” FASEB J., vol. 5, no. 7, pp. 2093-2098, 1991, doi: 10.1096/fasebj.5.7.2010061.

[3] L. M. Fischer et al., “Sex and menopausal status influence human dietary requirements for the nutrient choline,” Am. J. Clin. Nutr., vol. 85, no. 5, pp. 1275-1285, 2007, doi: 10.1093/ajcn/85.5.1275.

[4] M. Kohlmeier, K.-A. da Costa, L. M. Fischer, and S. H. Zeisel, “Genetic variation of folate-mediated one-carbon transfer pathway predicts susceptibility to choline deficiency in humans,” Proc. Natl. Acad. Sci. U.S.A., vol. 102, no. 44, pp. 16025-16030, 2005, doi: 10.1073/pnas.0504285102.

[5] K.-A. da Costa et al., “Choline deficiency increases lymphocyte apoptosis and DNA damage in humans,” Am. J. Clin. Nutr., vol. 84, no. 1, pp. 88-94, 2006, doi: 10.1093/ajcn/84.1.88.

[6] M. D. Niculescu et al., “Lymphocyte gene expression in subjects fed a low-choline diet differs between those who develop organ dysfunction and those who do not,” Am. J. Clin. Nutr., vol. 86, no. 1, pp. 230-239, 2007, doi: 10.1093/ajcn/86.1.230.

[7] N. Stefan et al., “Effect of essential phospholipids in metabolic dysfunction-associated steatotic liver disease: A randomised phase 4 clinical trial,” Liver Int., vol. 46, no. 5, Art. no. e70601, 2026, doi: 10.1111/liv.70601.

[8] S. S. Sedhom et al., “The impact of choline supplementation on oxidative stress and clinical outcomes among patients with non-alcoholic fatty liver disease: A randomized controlled study,” Ther. Adv. Chronic Dis., vol. 16, Art. no. 20406223251358659, 2025, doi: 10.1177/20406223251358659.

[9] T. Manuc et al., “Sylimarin versus essential phospholipids in metabolic associated steatotic liver disease (MASLD) - A prospective comparative randomized trial,” Maedica (Bucur), vol. 19, no. 1, pp. 9-16, 2024, doi: 10.26574/maedica.2024.19.1.9.

[10] L. Abenavoli et al., “Treatment with phosphatidylcholine of patients with nonalcoholic fatty liver disease: A prospective pilot study,” Minerva Gastroenterol. (Torino), vol. 68, no. 4, pp. 393-399, 2022, doi: 10.23736/S2724-5985.21.03066-7.

[11] A. L. Buchman et al., “Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients,” Gastroenterology, vol. 102, no. 4, pt. 1, pp. 1363-1370, 1992, PMID: 1551541.

[12] A. L. Buchman et al., “Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: Proof of a human choline requirement: A placebo-controlled trial,” JPEN J. Parenter. Enteral Nutr., vol. 25, no. 5, pp. 260-268, 2001, doi: 10.1177/0148607101025005260.

[13] M. R. Olthof, E. J. Brink, M. B. Katan, and P. Verhoef, “Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men,” Am. J. Clin. Nutr., vol. 82, no. 1, pp. 111-117, 2005, doi: 10.1093/ajcn/82.1.111.

[14] R. Tanaka-Kanegae, H. Kimura, and K. Hamada, “Pharmacokinetics of soy-derived lysophosphatidylcholine compared with that of glycerophosphocholine: A randomized controlled trial,” Biosci. Biotechnol. Biochem., vol. 88, no. 6, pp. 648-655, 2024, doi: 10.1093/bbb/zbae031.

[15] EFSA Panel on Dietetic Products, Nutrition and Allergies, “Scientific Opinion on the substantiation of health claims related to choline and contribution to normal lipid metabolism, maintenance of normal liver function, contribution to normal homocysteine metabolism, maintenance of normal neurological function, contribution to normal cognitive function, and brain and neurological development,” EFSA J., vol. 9, no. 4, Art. no. 2056, 2011, doi: 10.2903/j.efsa.2011.2056.